How to Microdose Tirzepatide to Maintain Weight Loss: What the Step-Down Trials Actually Show
People searching how to microdose tirzepatide to maintain weight loss want to keep the result on less drug. Nobody has trialed a true microdose for that. A 2026 Lancet trial did test the next best thing: stepping down to 5 mg.
16.6%
BELOW STARTING WEIGHT AT WEEK 112 AFTER STEPPING DOWN TO 5 MG (SURMOUNT-MAINTAIN)
9.9%
BELOW STARTING WEIGHT AT WEEK 112 AFTER SWITCHING TO PLACEBO
5 mg
LOWEST TIRZEPATIDE MAINTENANCE DOSE ON THE ZEPBOUND LABEL AND IN ANY MAINTENANCE TRIAL
Once the scale settles, the next question is usually about money and side effects. Do you have to stay on 10 or 15 mg of tirzepatide forever, or can a much smaller dose hold the line? Microdosing tirzepatide to maintain weight loss is the idea that a low, ongoing dose keeps appetite in check without the cost and nausea of the full one.
The evidence is narrower than the forums suggest, but it is no longer empty. Two maintenance trials, SURMOUNT-4 and SURMOUNT-MAINTAIN, show what happens when tirzepatide stops and what happens when the dose drops to 5 mg. A semaglutide study adds a third data point on stopping. None of them tested doses below 5 mg, and this article is clear about where the data ends.
Key takeaways
- •No clinical trial has tested a tirzepatide microdose (below 5 mg weekly) for maintaining weight loss.
- •In SURMOUNT-MAINTAIN (Lancet, 2026), adults who stepped down to tirzepatide 5 mg were 16.6% below their starting weight at week 112, versus 21.9% for those who stayed on 10 or 15 mg and 9.9% for those switched to placebo.
- •In SURMOUNT-4 (JAMA, 2024), stopping tirzepatide led to a 14.0% weight increase over 52 weeks, while continuing it produced a further 5.5% loss.
- •The Zepbound label lists 5 mg, 10 mg or 15 mg weekly as maintenance doses and states that 2.5 mg is not approved as a maintenance dose.
- •Hair loss was reported in 4% to 5% of people on tirzepatide versus 1% on placebo, and the label links it to weight reduction rather than a specific dose.
How do you microdose tirzepatide to maintain weight loss?
There is no tested protocol for microdosing tirzepatide to maintain weight loss. The lowest maintenance dose any trial has studied is 5 mg once weekly, and that is also the lowest maintenance dose on the label. Anything below it, or anything spaced further apart than weekly, is off-label and unstudied.
The Zepbound prescribing information starts tirzepatide at 2.5 mg weekly for 4 weeks, moves to 5 mg, and allows increases in 2.5 mg steps after at least 4 weeks on each dose. It then states: "The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg." The same section adds that 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage."
So the honest answer to "how" is a set of questions to bring to a prescriber rather than a dosing schedule. What does the maintenance evidence show at 5 mg? How fast does weight come back without drug? And what are the extra risks of measuring small doses by hand? The sections below take those in order.
Is 5 mg of tirzepatide enough to maintain weight loss?
Tirzepatide 5 mg held on to most of the weight for most people in the only trial that tested it as a step-down dose, but it held less than the full dose did. That trial is SURMOUNT-MAINTAIN, published by Horn and colleagues in the Lancet in 2026.
SURMOUNT-MAINTAIN ran for 112 weeks at 20 sites in the USA. Everyone first took tirzepatide at their maximum tolerated dose (MTD), either 10 mg or 15 mg, for 60 weeks. At week 60, 378 adults were randomly assigned in a 3:3:2 ratio to stay on their MTD, drop to 5 mg, or switch to placebo for another 52 weeks. At the start, participants averaged 46.6 years old, 113.8 kg and a BMI of 40.1, and 65% were women.
Weight loss from starting weight at week 112 (%)
Horn DB et al., Lancet 2026 (SURMOUNT-MAINTAIN, 378 randomized adults with obesity or overweight with a weight-related condition).
All three groups took the full dose for the first 60 weeks. The differences come from the final 52 weeks.
At week 112, the MTD group was 21.9% below its starting weight, the 5 mg group 16.6%, and the placebo group 9.9%. Compared with placebo, the difference was 12.0 percentage points for the full dose and 6.6 points for 5 mg. Both gaps were statistically significant.
The authors' conclusion is careful. Reducing to 5 mg "might provide a valuable alternative to discontinuation, although individuals' treatment response might vary." That is a step-down to the label's lowest maintenance dose, after more than a year at full dose. It is not evidence for doses smaller than 5 mg. The study was funded by Eli Lilly, which makes tirzepatide.
How many people regained weight on the lower dose?
About a quarter of people who stepped down to 5 mg regained enough weight to need rescue treatment, about three times the rate seen in those who stayed on the full dose. SURMOUNT-MAINTAIN let participants restart rescue tirzepatide from week 84 if they regained more than 50% of the weight they had lost.
Participants who regained more than half their loss and received rescue tirzepatide (%)
Horn DB et al., Lancet 2026 (SURMOUNT-MAINTAIN).
Counts were 11 of 138 on MTD, 35 of 142 on 5 mg and 60 of 90 on placebo.
Rescue therapy went to 8% of the MTD group, 25% of the 5 mg group and 67% of the placebo group. Put another way, three in four people on 5 mg avoided major regain over the year, while two in three on placebo did not. That spread is the practical meaning of "response might vary": the lower dose worked well for many people and not for a meaningful minority, and the trial abstract does not say how to tell them apart in advance.
What happens to weight when you stop tirzepatide?
Stopping tirzepatide leads most people to regain a large part of the weight within a year. The clearest evidence is SURMOUNT-4, a randomized withdrawal trial by Aronne and colleagues published in JAMA in 2024.
In SURMOUNT-4, 783 adults without diabetes took their maximum tolerated dose of tirzepatide (10 or 15 mg) for 36 weeks, losing a mean 20.9%. Then 670 of them were randomized 1:1 to keep taking tirzepatide or switch to placebo for 52 more weeks, across 70 sites in 4 countries.
Weight change from week 36 to week 88 (%)
Aronne LJ et al., JAMA 2024 (SURMOUNT-4, 670 randomized adults). Negative values are further loss; positive values are regain.
From week 36 to week 88, weight changed by -5.5% in people who stayed on tirzepatide and by +14.0% in people switched to placebo. Over the whole study, from week 0 to week 88, total weight reduction was 25.3% with tirzepatide and 9.9% with placebo.
Kept at least 80% of their earlier weight loss at week 88 (%)
Aronne LJ et al., JAMA 2024 (SURMOUNT-4).
89.5% of people on tirzepatide kept at least 80% of their lead-in loss, compared with 16.6% on placebo. The authors wrote that "withdrawing tirzepatide led to substantial regain of lost weight." This is the baseline any maintenance plan is measured against: zero drug does not hold the result for most people, and the question is how much drug does.
How do you microdose semaglutide or other GLP-1s to maintain weight?
No trial has tested a semaglutide microdose, or any other GLP-1 microdose, for maintaining weight loss. The semaglutide evidence, like tirzepatide's, shows what happens on full dose and after stopping, not on a small ongoing dose.
The STEP 1 trial extension, published by Wilding and colleagues in Diabetes, Obesity and Metabolism in 2022, followed 327 adults from STEP 1, from both the semaglutide and placebo arms, for a year after once-weekly treatment (semaglutide 2.4 mg or placebo) and lifestyle support stopped at week 68.
Semaglutide 2.4 mg: weight loss from starting weight (%)
Wilding JPH et al., Diabetes Obes Metab 2022 (STEP 1 extension, semaglutide group, adults without diabetes).
People on semaglutide had lost 17.3% by week 68. After stopping, they regained 11.6 percentage points by week 120, leaving a net loss of 5.6%. The authors also reported that cardiometabolic improvements "reverted towards baseline at week 120 for most variables." For a side-by-side look at the lowest doses each drug was tested at, see our guide to microdose semaglutide vs tirzepatide.
Does microdose tirzepatide cause hair loss?
Hair loss at microdoses of tirzepatide has not been studied, but the label data suggest it tracks weight loss more than dose. In the obesity trials summarized in the Zepbound prescribing information, hair loss was reported more often on tirzepatide than on placebo, and the rate was flat across doses.
Hair loss reported in adults with obesity or overweight (%)
ZEPBOUND prescribing information, Table 1 (DailyMed, accessed October 14, 2026).
Hair loss was reported in 1% on placebo, 5% on 5 mg, 4% on 10 mg and 5% on 15 mg, and the label describes it as "associated with weight reduction." A lower maintenance dose therefore may not protect hair by itself. What usually matters is the pace and size of weight loss, plus protein and overall intake.
Shedding after rapid weight loss tends to follow a predictable timeline, which we cover in why hair thins during GLP-1 weight loss. Bone is another tissue worth protecting during long-term treatment; see how a GLP-1 microdose relates to bone during weight loss.
Can you space out tirzepatide doses instead of lowering them?
Spacing tirzepatide doses further apart has not been tested for maintenance, and the label lists only once-weekly dosing. Every maintenance trial discussed here used weekly injections.
The Zepbound label puts tirzepatide's elimination half-life at about 5 to 6 days in people with overweight or obesity. With a half-life that short, an every-other-week schedule would let levels fall further before each injection than weekly dosing does, and nobody has measured what that does to appetite or regain. Stretching the interval is a different experiment from lowering the dose, and neither has trial data below 5 mg weekly.
What are the risks of measuring small tirzepatide doses?
The main practical risk of tirzepatide microdosing is getting the dose wrong. Labeled pens deliver fixed doses starting at 2.5 mg, so smaller amounts usually come from compounded vials drawn up by hand.
The FDA's page on unapproved GLP-1 drugs states that compounded drugs are not FDA approved and that the agency does not review them "for safety, effectiveness or quality before they are marketed." It also reports adverse events, some requiring hospitalization, from "patients measuring and self-administering incorrect doses of the drug." Any maintenance plan below the label belongs with a prescriber who can confirm the product, the concentration and the syringe markings.
So what does the evidence support for maintenance?
The evidence supports three things for tirzepatide maintenance. Staying on the full dose holds the most weight. Stepping down to 5 mg holds less but far more than stopping, for most people. Stopping entirely leads to substantial regain in most people.
The evidence does not yet cover doses below 5 mg, doses spaced more than a week apart, or plans that taper slowly toward zero. Those may turn out to work for some people. Today they are educated guesses, and anyone using one should track weight, waist and strength closely enough to notice regain early. The broader metabolic upside of staying on treatment is covered in our piece on GLP-1 benefits beyond weight loss.
The lowest tirzepatide maintenance dose with trial data is 5 mg a week. Below that, nobody has measured what happens.
Frequently asked questions
How do you microdose tirzepatide to maintain weight loss?
No trial has tested a tirzepatide microdose for weight maintenance, so there is no evidence-based way to do it. The lowest maintenance dose studied is 5 mg weekly: in SURMOUNT-MAINTAIN, people who stepped down to 5 mg after reaching their full dose were 16.6% below their starting weight at week 112. Any lower dose, or a longer gap between doses, is untested and is a decision for a prescriber.
Is microdosing tirzepatide effective for weight loss?
Microdosing tirzepatide has not been shown to be effective for weight loss or maintenance, because it has not been studied. The Zepbound label sets 5 mg, 10 mg or 15 mg weekly as maintenance doses and says the 2.5 mg starting dose is not approved for maintenance. Results reported online for smaller doses come from individual experience, not controlled trials.
What happens to weight when you stop tirzepatide?
Most people regain a large share of the weight after stopping tirzepatide. In SURMOUNT-4, people switched to placebo after 36 weeks of treatment regained weight, with a 14.0% increase from week 36 to week 88, while those who continued lost a further 5.5%. Only 16.6% of the placebo group kept at least 80% of their earlier loss, compared with 89.5% on tirzepatide.
Is 5 mg of tirzepatide enough to maintain weight loss?
For many people in SURMOUNT-MAINTAIN, 5 mg kept off much of the weight, but less than staying on the full dose. At week 112, the 5 mg group was 16.6% below baseline, compared with 21.9% for those who stayed on 10 or 15 mg and 9.9% for placebo. A quarter of the 5 mg group regained more than half their loss and needed rescue treatment, so response varied.
How do you microdose semaglutide to maintain weight?
There is no trial of a semaglutide microdose for maintenance either. What the evidence shows is what happens after stopping: in the STEP 1 extension, people who lost 17.3% on semaglutide 2.4 mg regained 11.6 percentage points within a year, leaving a net loss of 5.6% at week 120. Whether a smaller ongoing dose would prevent that has not been tested.
Does microdose tirzepatide cause hair loss?
Hair loss has not been studied at microdoses of tirzepatide. In the trials behind the Zepbound label, hair loss was reported in 5% of people on 5 mg, 4% on 10 mg and 5% on 15 mg, versus 1% on placebo, and the label says it was associated with weight reduction. Because the rate did not rise with dose, the speed of weight loss may matter more than the dose itself.
Can you take tirzepatide every other week for maintenance?
Every-other-week tirzepatide has not been tested in a trial, and the Zepbound label lists only once-weekly dosing. Tirzepatide has a half-life of about 5 to 6 days in people with overweight or obesity, so levels fall well below their weekly peak by the second week. Spacing out doses changes exposure in ways no study has measured for weight maintenance.
Is compounded tirzepatide safe for microdosing?
The FDA says compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before they are marketed. The agency has also received reports of adverse events, some requiring hospitalization, linked to people measuring and injecting incorrect doses. Small, hand-measured doses raise that measuring risk.
Clinical references
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026. doi:10.1016/S0140-6736(26)00656-2
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. doi:10.1001/jama.2023.24945
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. doi:10.1111/dom.14725
- ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, National Library of Medicine. Accessed October 14, 2026. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Accessed October 14, 2026. fda.gov
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for the physician, prescriber, pharmacist, or clinician responsible for your care. Tirzepatide is a prescription medicine, and taking it below its labeled maintenance doses or on a different schedule is off-label use that has not been tested in clinical trials. Charts show values reported in the cited studies and prescribing information. Do not lower, stop, space out, split, or share a dose without your prescriber. Severe or persistent abdominal pain, repeated vomiting, or signs of dehydration need prompt medical attention.